- Medicenna Therapeutics Corp MDNA11 Clinical Update Call TranscriptAug 09, 2023
- Medicenna Therapeutics Corp at Bloom Burton & Co Healthcare Investor Conference TranscriptApr 25, 2023
- Medicenna Therapeutics Corp at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Medicenna Therapeutics Corp at Guggenheim Healthcare Talks Oncology Day TranscriptFeb 09, 2023
- Q3 2023 Medicenna Therapeutics Corp Earnings Call TranscriptFeb 07, 2023$0.751 (-1.83%)Earnings
- Q2 2023 Medicenna Therapeutics Corp Earnings Call TranscriptNov 04, 2022$0.646 (-3.15%)Earnings
- Medicenna Therapeutics Corp Annual Shareholders Meeting TranscriptSep 21, 2022
- Q1 2023 Medicenna Therapeutics Corp Earnings Call TranscriptAug 15, 2022$0.98 (-8.41%)Earnings
- Q4 2022 Medicenna Therapeutics Corp Earnings Call TranscriptJun 22, 2022$0.9755 (+15.31%)Earnings
- Medicenna Therapeutics Corp at Bloom Burton & Co. Healthcare Investor Conference TranscriptMay 02, 2022
- Q3 2022 Medicenna Therapeutics Corp Earnings Call TranscriptFeb 09, 2022$1.87 (+1.08%)Earnings
- Q2 2022 Medicenna Therapeutics Corp Earnings Call TranscriptNov 12, 2021$2.05 (+0.74%)Earnings
- Medicenna Therapeutics Corp Annual Shareholders Meeting TranscriptSep 23, 2021
- Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Q1 2022 Medicenna Therapeutics Corp Earnings Call TranscriptAug 13, 2021$2.04 (-6.42%)Earnings
- Medicenna Therapeutics Corp MDNA11 Program Update Call TranscriptJul 27, 2021
- Q4 2021 Medicenna Therapeutics Corp Earnings Call TranscriptMay 28, 2021$3.89 (+1.83%)Earnings
- Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) TranscriptMar 02, 2021
- Medicenna Therapeutics Corp. - Special Call TranscriptDec 11, 2020
- Medicenna Therapeutics Corp. - Special Call TranscriptMar 25, 2020
- Medicenna Therapeutics Corp to Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results TranscriptNov 25, 2019
Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Thanks for joining our next session. My name is Matt Biegler; I'm an analyst on the emerging biotech team here at Oppenheimer. Pleased to introduce our next company, Medicenna, which I'm actually covering with an outperform rating. These guys are developing novel cytokine-based therapies including a novel IL-2 agonist called MDNA11, which you will hear more about.
Just a quick housekeeping note. If you want to ask a question, please type it into the box on the Wall Street Webcasting interface. I think it's at the right-hand side of your screen. So we are joined by CEO, Fahar Merchant. Fahar, the floor is yours.
Thank you, Matt. Thank you all for joining today's presentation for Medicenna. We will be presenting and putting out some forward-looking statements, so I would encourage you to look at our regulatory filings regarding risk factors, et cetera.
So Medicenna is a company that's really focused on developing and designing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)